Feldan Therapeutics Initiates FLD-103 Trial for Basal Cell Carcinoma
Feldan Therapeutics is conducting a clinical trial to evaluate the safety, tolerability, and efficacy of intralesional FLD-103 in patients with Basal Cell Carcinoma.
Company
Pharmaceutical intelligence for Feldan Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.